NCPA/NACDS Cost Study Will Counter OIG Conclusion On Medicaid Payments
The National Community Pharmacists Association and the National Association of Chain Drug Stores expect results of their study on actual pharmacy acquisition costs for Medicaid drugs to be available in November.
You may also be interested in...
Medicaid reimbursement to pharmacies should be adjusted to reflect the actual acquisition cost for brand name drugs, estimated at 21.84% below average wholesale price, a HHS Inspector General report states.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials